|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUČšIONALE
- The Moldovan Medical Journal
- The Moldovan Medical Journal
- The Moldovan Medical Journal 2022
- The Moldovan Medical Journal. Vol. 65, No 2, December 2022
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/23623
Title: | A new approach in the treatment of retinopathies and optic nerve atrophy using mesenchymal stem cells |
Authors: | Taralunga, Tatiana Paduca, Ala Nacu, Viorel |
Keywords: | stem cells;retinopathy;optic nerve atrophy |
Issue Date: | 2022 |
Publisher: | The Scientific Medical Association of the Republic of Moldova |
Citation: | TARALUNGA, Tatiana, PADUCA, Ala, NACU, Viorel. A new approach in the treatment of retinopathies and optic nerve atrophy using mesenchymal stem cells. In: The Moldovan Medical Journal. 2022, vol. 65, no 2, pp. 64-68. ISSN 2537-6381. https://doi.org/10.52418/moldovan-med-j.65-2.22.10 |
Abstract: | Background: The tissue engineering is the evolving science that combines cells, biomaterials and biochemical factors aimed at restoring, maintaining
and substituting different types of tissue. An important role is played by the use of the stem cells in various fields of medicine, including ophthalmology,
namely in cases of retinopathies and optic nerve atrophy.
Conclusions: Current treatment of the optic nerve atrophy is based on the etiological causes or late complications. Considering the availability of advanced
therapies, stem cell therapy offers a new approach in the treatment of the atrophy of the optic nerve. Being easy to harvest and cultivate, mesenchymal
stem cells are most commonly used in regenerative medicine, they can be induced to differentiate into cartilage, tendons, adipose tissue and other cell
lines. Mesenchymal stem cell harvesting has no ethical issues compared to embryonic stem cell harvesting. The major histocompatibility factor II is not
expressed on the surface of mesenchymal stem cells, and this great advantage allows their use in autologous or allogenic form. Mesenchymal stem cells
produce growth factors with paracrine action that are thought to activate endogenous repair mechanisms, due to these properties mesenchymal stem cells
have been used in several clinical studies in optic nerve disorders where immunomodulatory and neuroprotective properties have been demonstrated.
All of the properties mentioned above stand for the clinical use of mesenchymal stem cells in case of optic nerve atrophy. |
metadata.dc.relation.ispartof: | The Moldovan Medical Journal |
URI: | https://moldmedjournal.md/wp-content/uploads/2022/12/02-Moldovan-Med-J-2022-Vol65-No2.pdf https://doi.org/10.52418/moldovan-med-j.65-2.22.10 http://repository.usmf.md/handle/20.500.12710/23623 |
ISSN: | 2537-6373 2537-6381 |
Appears in Collections: | The Moldovan Medical Journal. Vol. 65, No 2, December 2022
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|